Talphera (TLPH) Liabilities and Shareholders Equity (2010 - 2026)
Talphera (TLPH) posted quarterly Liabilities and Shareholders Equity of $30.2 million for Q1 2026, up 101.1% year-over-year from $15.0 million in Q1 2025, and up 1.47% quarter-over-quarter from $29.7 million in Q4 2025.
Talphera (TLPH) Liabilities and Shareholders Equity (2010 - 2026) Analysis & Trends
Talphera's Liabilities and Shareholders Equity history runs 17 years deep, the most recent figure standing at $30.2 million for Q1 2026.
- In Q1 2026, Liabilities and Shareholders Equity rose 101.1% year-over-year to $30.2 million; the TTM figure through Mar 2026 stood at $107.1 million (up 35.44% YoY), while the FY2025 annual figure was $29.7 million, up 62.97% from the prior year.
- Liabilities and Shareholders Equity for Q1 2026 stood at $30.2 million, up from $29.7 million in the prior quarter.
- The five-year high for Liabilities and Shareholders Equity was $72.0 million in Q1 2022, with the low at $15.0 million in Q1 2025.
- The 5-year median for Liabilities and Shareholders Equity is $26.3 million (2023), against an average of $31.0 million.
- The sharpest annual moves came in 2023 and 2026: Liabilities and Shareholders Equity slumped 68.42% in 2023, then soared 101.1% in 2026.
- Talphera's Liabilities and Shareholders Equity stood at $47.5 million in 2022, then plunged by 57.05% to $20.4 million in 2023, then slipped by 10.59% to $18.2 million in 2024, then soared by 62.97% to $29.7 million in 2025, then advanced by 1.47% to $30.2 million in 2026.
- Business Quant data shows TLPH's Liabilities and Shareholders Equity at $30.2 million in Q1 2026, $29.7 million in Q4 2025, and $30.7 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | 43.71 Bn |
| 2 | Teva Pharmaceutical Industries | 42.95 Bn | 39.30 Bn | 2.15 Bn | 39.86 Bn |
| 3 | Zoetis | 31.58 Bn | 29.90 Bn | 1.05 Bn | 15.08 Bn |
| 4 | Takeda Pharmaceutical | 28.63 Bn | 22.83 Bn | 5.10 Bn | 98.27 Bn |
| 5 | United Therapeutics | 22.16 Bn | 19.49 Bn | 683.80 Mn | 7.22 Bn |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | 35.04 Bn |
| 7 | Neurocrine Biosciences | 15.53 Bn | 15.14 Bn | 935.80 Mn | 5.36 Bn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn | 13.56 Bn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.95 Bn | - | 6.18 Bn |
| 10 | Talphera | 89.95 Mn | 89.95 Mn | - | 26.81 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 26.81 Mn |
| Mar 31, 2026 | 30.16 Mn |
| Dec 31, 2025 | 29.72 Mn |
| Sep 30, 2025 | 30.74 Mn |
| Jun 30, 2025 | 16.52 Mn |
| Mar 31, 2025 | 15.00 Mn |
| Dec 31, 2024 | 18.24 Mn |
| Sep 30, 2024 | 21.01 Mn |
| Jun 30, 2024 | 24.86 Mn |
| Mar 31, 2024 | 28.77 Mn |
| Dec 31, 2023 | 20.40 Mn |
| Sep 30, 2023 | 23.26 Mn |
| Jun 30, 2023 | 17.73 Mn |
| Mar 31, 2023 | 26.29 Mn |
| Dec 31, 2022 | 47.49 Mn |
| Sep 30, 2022 | 48.31 Mn |
| Jun 30, 2022 | 56.13 Mn |
| Mar 31, 2022 | 71.97 Mn |
| Dec 31, 2021 | 77.89 Mn |
| Sep 30, 2021 | 72.26 Mn |